Blog RSS https://www.vumc.org/tb-center/ en TB Centers of Excellence - Grants Notice https://www.vumc.org/tb-center/funding-opportunities/tb-centers-excellence-grants-notice <span class="field field--name-title field--type-string field--label-hidden">TB Centers of Excellence - Grants Notice</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/staatsc" typeof="schema:Person" property="schema:name" datatype="">staatsc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 07/11/2022 - 10:02</span> <a href="/tb-center/blog-post-rss/379" class="feed-icon" title="Subscribe to TB Centers of Excellence - Grants Notice"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p><strong>TB Centers of Excellence for Training, Education and Medical Consultation (COE)</strong></p> <p>CDC plans to establish and fund up to four regionally-assigned Tuberculosis Centers of Excellence (TB COE) to facilitate efforts to prevent, treat, and control TB disease and latent TB infection (LTBI) in the United States (U.S.). The TB COE will focus on two major activities: (1) increasing knowledge, skills, and abilities for TB prevention and control through communication, education, and training activities, and; (2) improving sustainable evidence based TB clinical practices and patient care through the provision of expert medical consultation. The funds available for these core activities will be used to support TB and LTBI communication efforts, training, education, and medical consultation activities.</p> <p><strong>Funding Organization</strong></p> <p>Centers for Disease Control and Prevention - NCHHSTP</p> <p><strong>Closing Date for Applications</strong></p> <p>September 6th, 2022</p> <p> </p> <p>For more information, <a href="https://www.grants.gov/web/grants/view-opportunity.html?oppId=336618">https://www.grants.gov/web/grants/view-opportunity.html?oppId=336618</a></p> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Mon, 11 Jul 2022 15:02:20 +0000 staatsc 379 at https://www.vumc.org/tb-center TB Elimination Alliance Announces 2022-2023 Mini-Grant Program https://www.vumc.org/tb-center/funding-opportunities/tb-elimination-alliance-announces-2022-2023-mini-grant-program <span class="field field--name-title field--type-string field--label-hidden">TB Elimination Alliance Announces 2022-2023 Mini-Grant Program</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/staatsc" typeof="schema:Person" property="schema:name" datatype="">staatsc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 07/08/2022 - 08:57</span> <a href="/tb-center/blog-post-rss/378" class="feed-icon" title="Subscribe to TB Elimination Alliance Announces 2022-2023 Mini-Grant Program"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>The <a href="https://tbeliminationalliance.org/">Tuberculosis (TB) Elimination Alliance (TEA)</a> is offering Mini-Grants to organizations serving Asian American (AA), Native Hawaiian, and Pacific Islander (NH/PI) communities that are disproportionately impacted by latent TB infection (LTBI) and/or TB. Additional preference is given to organizations currently serving Asian/Asian American (A/AA) and NH/PI populations with an interest in expanding to non-US born Latino American, and US born African American communities.</p> <p>Mini-Grant proposals must align with TEA’s priority areas and activities that reflect community engagement and education, provider education, and/or quality improvement.</p> <p>Up to 15 awards will be provided to selected organizations. Each award amount will be between $10,000 and $30,000. <strong>Deadline to apply is Friday, August 5 by 5:00pm local time. </strong></p> <p>For more information please visit, <a href="https://tbeliminationalliance.org/2022-2023-tb-elimination-alliance-mini-grant-program-request-for-funding-proposal/">https://tbeliminationalliance.org/2022-2023-tb-elimination-alliance-mini-grant-program-request-for-funding-proposal/</a></p> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Fri, 08 Jul 2022 13:57:45 +0000 staatsc 378 at https://www.vumc.org/tb-center NIAID June 2022 Council-Approved Concepts https://www.vumc.org/tb-center/funding-opportunities/niaid-june-2022-council-approved-concepts <span class="field field--name-title field--type-string field--label-hidden">NIAID June 2022 Council-Approved Concepts</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/staatsc" typeof="schema:Person" property="schema:name" datatype="">staatsc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 06/28/2022 - 13:15</span> <a href="/tb-center/blog-post-rss/375" class="feed-icon" title="Subscribe to NIAID June 2022 Council-Approved Concepts"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. Concepts reveal possible initiatives or give you ideas for an investigator-initiated application.</p> <p> </p> <p><strong>Analyzing Early Events in Tuberculosis (TB) and TB/HIV Infection To Identify Interventional Targets</strong></p> <p><strong>Request for Applications—proposed FY 2024 initiative</strong></p> <p><strong>Objective:</strong> Early events associated with <em>Mycobacterium tuberculosis</em> (Mtb) infection are not well understood. However, studies delineating the initial stage of Mtb infection may identify unique targets for more effective vaccine adjuvants and immunomodulators, as well as improved biomarkers to advance prevention and therapy of TB. The objectives of this initiative are to better understand how Mtb evades and disrupts host immunity at the earliest stages of infection, and how myeloid (macrophages, dendritic cells, eosinophils), lymphoid (T cells, B cells, innate lymphoid cells) and non-immune cells (alveolar epithelial cells, pneumocytes, vascular) in the airway and lung interact with Mtb and each other. Furthermore, delineating the effects of HIV co-infection on immune mechanisms during early Mtb infection will facilitate the development of effective immune-based interventions for people living with HIV.</p> <p><strong>Contact:</strong> <br /> Robert Mahon<br /><a data-content="body-anchor-robert.mahon@nih.gov" href="mailto:robert.mahon@nih.gov" id="anch_373">robert.mahon@nih.gov</a></p> <p> </p> <hr /><p><strong>Consortium for Design of TB Drug Regimens</strong></p> <p><strong>Request for Applications—proposed FY 2024 initiative</strong></p> <p><strong>Objective:</strong> To establish a consortium of tuberculosis (TB) preclinical and clinical experts to systematically refine preclinical models with clinical data and identify the most efficacious combination regimens for future clinical testing to optimize relapse-free TB treatment.</p> <p><strong>Contact:</strong><br /> Barbara Laughon<br /><a data-content="body-anchor-blaughon@mail.nih.gov" href="mailto:blaughon@mail.nih.gov" id="anch_366">blaughon@mail.nih.gov</a></p> <hr /><p><strong><em>Mycobacterium tuberculosis </em>Quality Assessment (TBQA) Program</strong></p> <p><strong>Request for Proposals—proposed FY 2024 initiative</strong></p> <p><strong>Objective:</strong> TBQA will 1) support the ability of laboratories to reliably perform study-specified <em>Mycobacterium tuberculosis</em> (Mtb) tests; 2) evaluate Mtb technologies and specimen processes for use in clinical investigations; 3) disseminate technical and scientific data; 4) perform late-stage assay validation and/or Mtb assay testing of clinical samples in a CLIA-certified laboratory (Option); and 5) support public health emergency needs (Option). The TBQA will serve NIAID-sponsored and collaborating clinical trial networks and cohorts as well as individual grantees conducting research in and outside the United States. Examples of NIAID-sponsored Networks include the Adult AIDS Clinical Trials Group (ACTG), the International Maternal Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT), and the HIV Vaccine Trials Network (HVTN). Examples of NIAID-sponsored TB cohorts include the India and Brazil Regional Prospective Observational Research for Tuberculosis (RePORT).</p> <p><strong>Contact:</strong> <br /> Isaac Elliott<br /><a data-content="body-anchor-isaac.elliott@nih.gov" href="mailto:isaac.elliott@nih.gov" id="anch_375">isaac.elliott@nih.gov</a></p> <p> </p> <p>You can find more information <a href="https://www.niaid.nih.gov/grants-contracts/june-2022-daids-council-approved-concepts">here</a></p> <p> </p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=32" hreflang="und">NIH</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Tue, 28 Jun 2022 18:15:27 +0000 staatsc 375 at https://www.vumc.org/tb-center Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP), due September 07, 2022 https://www.vumc.org/tb-center/funding-opportunities/sustained-release-antivirals-treatment-or-prevention-hiv-or-treatment-latent <span class="field field--name-title field--type-string field--label-hidden">Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP), due September 07, 2022</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/staatsc" typeof="schema:Person" property="schema:name" datatype="">staatsc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 06/17/2022 - 12:45</span> <a href="/tb-center/blog-post-rss/374" class="feed-icon" title="Subscribe to Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP), due September 07, 2022"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Open Date (Earliest Submission Date): September 07, 2022</p> <p>Expiration Date: May 08, 2025</p> <p>The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.</p> <p>This Notice also encourages applications to develop once-a-month SR/LA strategies for treatment of latent TB and hepatitis B</p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-22-042.html?utm_campaign=+51774734&amp;utm_content=&amp;utm_medium=email&amp;utm_source=govdelivery&amp;utm_term=">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-22-042.html?utm…</a></p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=46" hreflang="und">NIAID</a>, <a href="/tb-center/funding-opportunities?tag=58" hreflang="und">TB</a>, <a href="/tb-center/funding-opportunities?tag=86" hreflang="und">LTBI</a>, <a href="/tb-center/funding-opportunities?tag=34" hreflang="und">HIV</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Fri, 17 Jun 2022 17:45:13 +0000 staatsc 374 at https://www.vumc.org/tb-center January 2022 DAIDS Council-Approved Concepts https://www.vumc.org/tb-center/funding-opportunities/january-2022-daids-council-approved-concepts <span class="field field--name-title field--type-string field--label-hidden">January 2022 DAIDS Council-Approved Concepts</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/vanselhj-0" typeof="schema:Person" property="schema:name" datatype="">vanselhj</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 03/18/2022 - 17:33</span> <a href="/tb-center/blog-post-rss/369" class="feed-icon" title="Subscribe to January 2022 DAIDS Council-Approved Concepts"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Notice of Special Interest (NOSI)—Identifying Immune Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection</p> <p>Notice of Special Interest—proposed FY 2023 initiative</p> <p><strong>Contact</strong>:<br /> Josh Radke<br /><a data-content="body-anchor-josh.radke@nih.gov" href="mailto:josh.radke@nih.gov" id="anch_421">josh.radke@nih.gov</a></p> <p><strong>Objective</strong>: NIAID has a specific interest in research toward understanding the role cell death mechanisms (CDMs) play in response to <em>Mycobacterium tuberculosis</em> (Mtb) infection, how Mtb subverts cell death pathways to promote infection, and to identify cellular targets that could be exploited as potential host-directed therapies to treat Mtb and Mtb/HIV co-infection.</p> <p><a href="https://www.niaid.nih.gov/grants-contracts/january-2022-daids-council-approved-concepts#05">https://www.niaid.nih.gov/grants-contracts/january-2022-daids-council-approved-concepts#05</a></p> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Fri, 18 Mar 2022 22:33:12 +0000 vanselhj 369 at https://www.vumc.org/tb-center Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed), due 06/08/2022 https://www.vumc.org/tb-center/funding-opportunities/biomarker-signatures-tb-infection-young-children-and-without-hiv-r01-clinical <span class="field field--name-title field--type-string field--label-hidden">Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed), due 06/08/2022</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/vanselhj-0" typeof="schema:Person" property="schema:name" datatype="">vanselhj</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 03/09/2022 - 12:13</span> <a href="/tb-center/blog-post-rss/368" class="feed-icon" title="Subscribe to Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed), due 06/08/2022"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Open Date (Earliest Submission Date): May 08, 2022</p> <p>Expiration Date: June 09, 2022</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to advance research to discover and validate novel biomarkers of Tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-015.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-015.html</a></p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=58" hreflang="und">TB</a>, <a href="/tb-center/funding-opportunities?tag=34" hreflang="und">HIV</a>, <a href="/tb-center/funding-opportunities?tag=99" hreflang="und">Pediatrics</a>, <a href="/tb-center/funding-opportunities?tag=46" hreflang="und">NIAID</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Wed, 09 Mar 2022 18:13:42 +0000 vanselhj 368 at https://www.vumc.org/tb-center Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed), due 07/08/2022 https://www.vumc.org/tb-center/funding-opportunities/improved-drug-susceptibility-testing-dst-tuberculosis-r01-clinical-trial-not <span class="field field--name-title field--type-string field--label-hidden">Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed), due 07/08/2022</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/vanselhj-0" typeof="schema:Person" property="schema:name" datatype="">vanselhj</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 03/09/2022 - 12:01</span> <a href="/tb-center/blog-post-rss/367" class="feed-icon" title="Subscribe to Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed), due 07/08/2022"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Open Date (Earliest Submission Date): June 08, 2022</p> <p>Expiration Date: July 09, 2022</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-016.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-016.html</a></p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=58" hreflang="und">TB</a>, <a href="/tb-center/funding-opportunities?tag=46" hreflang="und">NIAID</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Wed, 09 Mar 2022 18:01:53 +0000 vanselhj 367 at https://www.vumc.org/tb-center Contract Solicitation - 2022 NIAID Omnibus Broad Agency Announcement https://www.vumc.org/tb-center/funding-opportunities/contract-solicitation-2022-niaid-omnibus-broad-agency-announcement <span class="field field--name-title field--type-string field--label-hidden">Contract Solicitation - 2022 NIAID Omnibus Broad Agency Announcement</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/linharlc" typeof="schema:Person" property="schema:name" datatype="">linharlc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 01/20/2022 - 15:45</span> <a href="/tb-center/blog-post-rss/366" class="feed-icon" title="Subscribe to Contract Solicitation - 2022 NIAID Omnibus Broad Agency Announcement"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p><strong>NIAID 2022 OMNIBUS BROAD AGENCY ANNOUNCEMENT (BAA) NO. HHS-NIH-NIAID-BAA2022-1 </strong>contains four (4) distinct Research Areas, each with specified closing date and time.   The proposal due date of March 18, 2022, specified in this solicitation posting, is the due date for Research Area 003 only.  An Amendment will be issued at a later date to update the proposal due date for responses to Research Areas 001, 002, 004.  The proposal due dates for each Research Area are identified below:</p> <p><u>Research Area 001</u> - <em>Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases</em> </p> <p>Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022</p> <p><u>Research Area 002</u> - <em>Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases</em></p> <p>Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022</p> <p><u>Research Area 003</u> - <em>The Antiviral Program for Pandemics (APP): Development of Antivirals for Specific RNA Viral Families of Pandemic Potential</em></p> <p>Proposals Due Date and Time - 3:00 PM Eastern Time on March 18, 2022</p> <p><u>Research Area 004</u> - <em>Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections (AMR), and Emerging Infectious Diseases</em></p> <p>Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022</p> <p>For more information click <a href="https://sam.gov/opp/7be6deac410e4e4789555c72254d3f4d/view?utm_campaign=%2050765159&amp;utm_content=&amp;utm_medium=email&amp;utm_source=govdelivery&amp;utm_term=">HERE</a>!!</p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=32" hreflang="und">NIH</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Thu, 20 Jan 2022 21:45:58 +0000 linharlc 366 at https://www.vumc.org/tb-center September 2021 NIAID Council-Approved Concepts https://www.vumc.org/tb-center/funding-opportunities/september-2021-niaid-council-approved-concepts <span class="field field--name-title field--type-string field--label-hidden">September 2021 NIAID Council-Approved Concepts</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/linharlc" typeof="schema:Person" property="schema:name" datatype="">linharlc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 10/28/2021 - 13:41</span> <a href="/tb-center/blog-post-rss/364" class="feed-icon" title="Subscribe to September 2021 NIAID Council-Approved Concepts"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b>Improved Drug Susceptibility Testing (DST) for Tuberculosis!</b></span></span></span></p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><u>Request for Applications—proposed FY 2023 initiative</u></span></span></span></p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b>Objective:</b> To support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point-of-care DST and companion diagnostics for new TB drugs.</span></span></span></p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b>Description:</b> This concept would further the development of new diagnostic technologies for TB DST with an emphasis on rapid, point-of-care, low complexity assays. As new drugs move forward in the pipeline, there is a need for companion DST diagnostics for new drugs to ensure new drugs are used most effectively. Current phenotypic methods for determining drug resistance (DR) provide clinically relevant drug susceptibility information but have limitations. For example, the gold standard relies on culture, requires time for growth, and does not provide a result for many days. The program would solicit highly innovative DST assays, including phenotypic DST that may rely on a readout that does not require full growth as in traditional DST assays. Innovative technologies beyond nucleic acid amplification tests will be encouraged. This effort is anticipated to include exploratory work that would further improve our knowledge of genotypic and phenotypic correlates of clinical DR, which can be complex. Research that leverages the rapid advances in diagnostic technologies for COVID-19 applied to TB are also encouraged. Furthermore, this effort would be targeted to technology holders partnered with academic, clinical, and laboratory colleagues with TB diagnostic expertise.</span></span></span></p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Contact: </span></span></span><span style="font-family: Calibri, sans-serif; font-size: 11pt;">Karen Lacourciere</span></p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><a href="mailto:lacourcierek@niaid.nih.gov">lacourcierek@niaid.nih.gov</a></span></span></span></p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif">240-627-3297</span></span></span></p> <p style="margin-bottom:10px">Click <a href="https://www.niaid.nih.gov/grants-contracts/september-2021-dmid-council-approved-concepts#05">here</a> for more information!</p> <h2><p></p></h2> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Thu, 28 Oct 2021 18:41:22 +0000 linharlc 364 at https://www.vumc.org/tb-center NIAID Funding Opportunity: Brazil Regional Prospective Observational Research in Tuberculosis https://www.vumc.org/tb-center/funding-opportunities/niaid-funding-opportunity-brazil-regional-prospective-observational-research <span class="field field--name-title field--type-string field--label-hidden">NIAID Funding Opportunity: Brazil Regional Prospective Observational Research in Tuberculosis</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/linharlc" typeof="schema:Person" property="schema:name" datatype="">linharlc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 08/06/2021 - 16:49</span> <a href="/tb-center/blog-post-rss/326" class="feed-icon" title="Subscribe to NIAID Funding Opportunity: Brazil Regional Prospective Observational Research in Tuberculosis"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Brazil Regional Prospective Observational Research in Tuberculosis (RePORT) (U01 Clinical Trial Not Allowed)</p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Application open date: November 08, 2021</span></span></span></p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Expiration Date: December 09, 2021</span></span></span></p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The purpose of this Funding Opportunity Announcement (FOA) is to support a Brazil-US Regional Prospective Observational Research in Tuberculosis (RePORT) network to advance TB and TB/HIV science. The RePORT Brazil network will leverage and build upon Brazilian cohorts currently following adult and pediatric populations with active TB disease and their contacts or other high TB-risk individuals to address key research questions of regional and global interest. Specific areas supported under this program include, but are not limited to, research and development projects in TB/HIV in the areas of molecular epidemiology, diagnostics, biomarkers, vaccine development, and the impact of co-morbidities such as HIV and diabetes. Research outcomes should be capable of advancing tools with public health impact or of influencing decision making in TB public health to inform stakeholders on the best practices for early prevention, diagnosis, and clinical management of TB and TB/HIV.</span></span></span></p> <p style="margin-bottom:10px">Click <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-304.html?utm_campaign=+48995255&amp;utm_content=&amp;utm_medium=email&amp;utm_source=govdelivery&amp;utm_term=">here</a> for more information about this funding opportunity!</p> <p> </p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=58" hreflang="und">TB</a>, <a href="/tb-center/funding-opportunities?tag=19" hreflang="und">RePORT-Brazil</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Fri, 06 Aug 2021 21:49:03 +0000 linharlc 326 at https://www.vumc.org/tb-center June 2021 DAIDS Council-Approved Concepts https://www.vumc.org/tb-center/funding-opportunities/june-2021-daids-council-approved-concepts <span class="field field--name-title field--type-string field--label-hidden">June 2021 DAIDS Council-Approved Concepts</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/linharlc" typeof="schema:Person" property="schema:name" datatype="">linharlc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 07/14/2021 - 09:43</span> <a href="/tb-center/blog-post-rss/323" class="feed-icon" title="Subscribe to June 2021 DAIDS Council-Approved Concepts"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. Concepts reveal possible initiatives or give you ideas for an investigator-initiated application.</span></span></span></p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b>FY 2022 Concepts</b></span></span></span></p> <ul><li style="margin-left:8px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b>Brazil Regional Prospective Observational Research in Tuberculosis (RePORT)</b></span></span></span></li> </ul><p style="margin-left:48px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><u>Objective</u>: The primary objective of this initiative is to enable a network of Brazilian and U.S. scientists to advance current understanding of the community, host, and microbial factors that impact outcomes of tuberculosis (TB) infection and TB disease, especially among persons with HIV (PWH), including drug-resistant (DR)-TB, to facilitate developing tools to improve treatment outcomes at the individual level and inform strategies to curtail the TB epidemic at the public health level.</span></span></span></p> <p style="margin-left:48px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">To achieve this, the initiative will support a Brazil-U.S. Regional Prospective Observational Research in Tuberculosis (RePORT) network that will leverage the robust clinical research infrastructure that exists within Brazil to capacitate a wide range of research.</span></span></span></p> <p style="margin-bottom:10px; margin-left:48px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><i>Contact:  <a href="https://ned.nih.gov/search/ViewDetails.aspx?NIHID=0010118655" style="color:#0563c1; text-decoration:underline">Dr Sudha Srinivasan</a></i></span></span></span></p> <p style="margin-bottom:10px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b>FY 2023 Concepts</b></span></span></span></p> <ul><li style="margin-left:8px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b>South Africa Regional Prospective Observational Research in Tuberculosis (RePORT)</b></span></span></span></li> </ul><p style="margin-left:48px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><u>Objective</u>: The primary objective of this initiative is to enable a network of South African and U.S. scientists to advance current understanding of the community, host, and microbial factors that impact outcomes of tuberculosis (TB) infection and TB disease, especially among persons with HIV (PWH), including drug-resistant TB, to facilitate development of tools to improve treatment outcomes at the individual level and to inform strategies to curtail the TB epidemic at the public health level.</span></span></span></p> <p style="margin-left:48px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">To achieve this, the initiative will support a South Africa-U.S. Regional Prospective Observational Research in Tuberculosis (RePORT) network that will leverage the robust clinical research infrastructure that exists within South Africa to capacitate this research.</span></span></span></p> <p style="margin-left:48px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><i>Contact:  <a href="https://ned.nih.gov/search/ViewDetails.aspx?NIHID=0010118655" style="color:#0563c1; text-decoration:underline">Dr Sudha Srinivasan</a></i></span></span></span></p> <ul><li style="margin-left:8px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b>RePORT International Coordinating Center (RICC)</b></span></span></span></li> </ul><p style="margin-left:48px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><u>Objective</u>: The primary objective of this initiative is to advance tuberculosis (TB) and TB/HIV research by supporting coordination of global research efforts undertaken by the various in-country Regional Prospective Observational Research for Tuberculosis (RePORT) networks and other research partners. The RePORT International Coordinating Center (RICC) enables coordination and acceleration of research across the six RePORT countries (India, Brazil, South Africa, China, Indonesia, and Philippines) and fosters a synergistic approach. This will allow for maximizing resources, validating research findings, and generating globally applicable research outcomes in a timely manner.</span></span></span></p> <p style="margin-left:48px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><i>Contact:  <a href="https://ned.nih.gov/search/ViewDetails.aspx?NIHID=0010118655" style="color:#0563c1; text-decoration:underline">Dr Sudha Srinivasan</a></i></span></span></span></p> <ul><li style="margin-left:8px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><b>Biomarker Signatures of Tuberculosis Infection in Young Children With and Without HIV</b></span></span></span></li> </ul><p style="margin-left:48px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><u>Objective:</u> The goal of this initiative is to advance research to discover and validate novel biomarkers of tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.</span></span></span></p> <p style="margin-bottom:10px; margin-left:48px"><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif"><i>Contact: <a href="https://ned.nih.gov/search/ViewDetails.aspx?NIHID=0012060462" style="color:#0563c1; text-decoration:underline">Patrick Jean-Philippe</a></i></span></span></span></p> <p style="margin-bottom:10px; margin-left:48px">Click <a href="https://www.niaid.nih.gov/grants-contracts/june-2021-daids-council-approved-concepts#01">here</a> for more information!</p> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Wed, 14 Jul 2021 14:43:32 +0000 linharlc 323 at https://www.vumc.org/tb-center Advancing Vaccine Adjuvant Research for Tuberculosis (TB) https://www.vumc.org/tb-center/funding-opportunities/advancing-vaccine-adjuvant-research-tuberculosis-tb <span class="field field--name-title field--type-string field--label-hidden">Advancing Vaccine Adjuvant Research for Tuberculosis (TB)</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/linharlc" typeof="schema:Person" property="schema:name" datatype="">linharlc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 05/03/2021 - 11:34</span> <a href="/tb-center/blog-post-rss/319" class="feed-icon" title="Subscribe to Advancing Vaccine Adjuvant Research for Tuberculosis (TB)"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Solicitation for BAA-DAIT-75N93021R00008 entitled, "Advancing Vaccine Adjuvant Research for Tuberculosis (TB)"</p> <p>Contract Opportunity Type: Solicitation<br />  </p> <p>The goal of this program is to further the development of TB vaccines through sideby-side comparisons of adjuvants in combination with TB immunogens, and to establish immunological profiles of adjuvants that work through different mechanisms, facilitating the identification of the most promising adjuvant:Mtb immunogen candidates for clinical development and potential immune correlates of protection. The range of adjuvants to be evaluated may include novel classes of adjuvants being developed for other infections and immune-oncology therapeutics, as well as adjuvants already being developed for TB vaccines. It is anticipated that one cost reimbursement, completion type contract will be awarded for a five [5]-year period of performance beginning on or about 7/22/22.<br /> NIAID anticipates that the average annual total cost (direct and indirect costs combined) is $4 million per contract. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five [5] years. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about April, 28, 2021, and may be accessed through <strong><a href="https://beta.sam.gov/opp/f87d60b154e44aaea4be8a12bfdd03bc/view?utm_campaign=%2047669162&amp;utm_content=&amp;utm_medium=email&amp;utm_source=govdelivery&amp;utm_term=">here</a></strong>. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.</p> <p>Published: Apr 28, 2021 12:41 pm EDT<br /> Offers Due: Aug 10, 2021 03:00 pm EDT</p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=32" hreflang="und">NIH</a>, <a href="/tb-center/funding-opportunities?tag=58" hreflang="und">TB</a>, <a href="/tb-center/funding-opportunities?tag=46" hreflang="und">NIAID</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Mon, 03 May 2021 16:34:38 +0000 linharlc 319 at https://www.vumc.org/tb-center Postdoctoral Fellowship opportunity in Global HIV & TB Research https://www.vumc.org/tb-center/funding-opportunities/postdoctoral-fellowship-opportunity-global-hiv-tb-research <span class="field field--name-title field--type-string field--label-hidden">Postdoctoral Fellowship opportunity in Global HIV &amp; TB Research</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/linharlc" typeof="schema:Person" property="schema:name" datatype="">linharlc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 04/26/2021 - 10:02</span> <a href="/tb-center/blog-post-rss/318" class="feed-icon" title="Subscribe to Postdoctoral Fellowship opportunity in Global HIV &amp; TB Research"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><h3 id="content">Post-Doctoral Research Fellowships for Global HIV and TB Public Health Programs</h3> <p>The mission of this fellowship program is to recruit, mentor, and train scientist-practitioners to conduct global HIV and TB research and to develop the translational and applied skills necessary to implement and support high-quality HIV and TB public health programs in global settings. The goal of this fellowship is to attract and support recent recipients of doctoral degrees to understand the underpinnings of interventional epidemiology and to prepare them for a career operating at the intersection of science and practice in global public health. The selected candidates will be in the Division of Global HIV &amp; TB (DGHT) at the Centers for Disease Control and Prevention (CDC), headquartered in Atlanta, GA. The DGHT Office of the Director (DGHT OD) is the lead for the program. Fellows will also be paired with DGHT’s programmatic or data branches on various projects throughout their fellowship.</p> <p>The deadline to apply to this fellowship is <strong>June 30, 2021</strong>. The fellowship is scheduled to begin <strong>Fall 2021</strong>, subject to availability of funds.</p> <p>Click <a href="https://www.cdc.gov/globalhivtb/who-we-are/careers/fellowships/fellowship.html">here</a> for more information about this fellowship!</p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=54" hreflang="und">CDC</a>, <a href="/tb-center/funding-opportunities?tag=58" hreflang="und">TB</a>, <a href="/tb-center/funding-opportunities?tag=34" hreflang="und">HIV</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Mon, 26 Apr 2021 15:02:17 +0000 linharlc 318 at https://www.vumc.org/tb-center Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed) https://www.vumc.org/tb-center/funding-opportunities/innovation-tuberculosis-vaccine-discovery-itvd-r61r33-clinical-trial-not <span class="field field--name-title field--type-string field--label-hidden">Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/linharlc" typeof="schema:Person" property="schema:name" datatype="">linharlc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 02/24/2021 - 09:04</span> <a href="/tb-center/blog-post-rss/313" class="feed-icon" title="Subscribe to Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Application Due Date: June 30, 2021. Letter of Intent Due Date: 30 days prior to the application due date.  Expires: July 01, 2021.</p> <p>The purpose of this funding opportunity is to support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-007.html?utm_campaign=+46333793&amp;utm_content=&amp;utm_medium=email&amp;utm_source=govdelivery&amp;utm_term=">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-007.html?utm_campaign=+46333793&amp;utm_content=&amp;utm_medium=email&amp;utm_source=govdelivery&amp;utm_term=</a></p> <p> </p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=32" hreflang="und">NIH</a>, <a href="/tb-center/funding-opportunities?tag=46" hreflang="und">NIAID</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Wed, 24 Feb 2021 15:04:40 +0000 linharlc 313 at https://www.vumc.org/tb-center Notice of Special Interest (NOSI): Secondary Analysis of Existing Datasets for Advancing Immune-mediated and Infectious Disease Research https://www.vumc.org/tb-center/funding-opportunities/notice-special-interest-nosi-secondary-analysis-existing-datasets-advancing <span class="field field--name-title field--type-string field--label-hidden">Notice of Special Interest (NOSI): Secondary Analysis of Existing Datasets for Advancing Immune-mediated and Infectious Disease Research</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/linharlc" typeof="schema:Person" property="schema:name" datatype="">linharlc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Wed, 02/17/2021 - 14:32</span> <a href="/tb-center/blog-post-rss/312" class="feed-icon" title="Subscribe to Notice of Special Interest (NOSI): Secondary Analysis of Existing Datasets for Advancing Immune-mediated and Infectious Disease Research"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>First Application Due Date: June 16, 2021. Expires: May 8, 2024.</p> <p>This Notice of Special Interest (NOSI) is to support projects that use data, alone or in combination, to address scientific questions and knowledge gaps in basic or clinical research in immune-mediated and infectious diseases.</p> <p>Must submit to: <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-195.html">PA-20-195</a> - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)</p> <p><a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-011.html?utm_campaign=+46277012&amp;utm_content=&amp;utm_medium=email&amp;utm_source=govdelivery&amp;utm_term=">https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-011.html</a></p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=46" hreflang="und">NIAID</a>, <a href="/tb-center/funding-opportunities?tag=39" hreflang="und">NIMH</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Wed, 17 Feb 2021 20:32:03 +0000 linharlc 312 at https://www.vumc.org/tb-center Supporting, Mobilizing, and Accelerating Research for TB Elimination (SMART4TB) https://www.vumc.org/tb-center/funding-opportunities/supporting-mobilizing-and-accelerating-research-tb-elimination-smart4tb <span class="field field--name-title field--type-string field--label-hidden">Supporting, Mobilizing, and Accelerating Research for TB Elimination (SMART4TB)</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/linharlc" typeof="schema:Person" property="schema:name" datatype="">linharlc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Tue, 02/02/2021 - 12:02</span> <a href="/tb-center/blog-post-rss/311" class="feed-icon" title="Subscribe to Supporting, Mobilizing, and Accelerating Research for TB Elimination (SMART4TB)"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Application Due Date: <em>Pending</em></p> <p>The goals of this planned award are:</p> <p>1) to stimulate the development and implementation of new tools and approaches to accelerate the prevention, detection and management of tuberculosis in adults and children and</p> <p>2) strengthen local capacity to design, implement, disseminate and use findings from TB research.</p> <p>Anticipated Award Date: 9/30/2021</p> <p><a href="https://www.usaid.gov/business-forecast/search/award/89532a8c84?search=&amp;location=All&amp;ouid=All&amp;page=9">https://www.usaid.gov/business-forecast/search/award/89532a8c84?search=&amp;location=All&amp;ouid=All&amp;page=9</a></p> <p> </p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=93" hreflang="und">USAID</a>, <a href="/tb-center/funding-opportunities?tag=58" hreflang="und">TB</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Tue, 02 Feb 2021 18:02:52 +0000 linharlc 311 at https://www.vumc.org/tb-center Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed), expires June 16, 2021 https://www.vumc.org/tb-center/funding-opportunities/tuberculosis-research-advancement-centers-p30-clinical-trials-not-allowed <span class="field field--name-title field--type-string field--label-hidden">Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed), expires June 16, 2021</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/linharlc" typeof="schema:Person" property="schema:name" datatype="">linharlc</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 01/08/2021 - 15:58</span> <a href="/tb-center/blog-post-rss/309" class="feed-icon" title="Subscribe to Tuberculosis Research Advancement Centers (P30 Clinical Trials Not Allowed), expires June 16, 2021"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Application Due Date: June 15, 2021</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-001.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-001.html</a></p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=32" hreflang="und">NIH</a>, <a href="/tb-center/funding-opportunities?tag=46" hreflang="und">NIAID</a>, <a href="/tb-center/funding-opportunities?tag=58" hreflang="und">TB</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Fri, 08 Jan 2021 21:58:11 +0000 linharlc 309 at https://www.vumc.org/tb-center Using Syndemics to Understand HLBS Disease Emergence and Progression in People with HIV (PWH)(R01 Clinical Trial Not Allowed), expires 12/15/2021 https://www.vumc.org/tb-center/funding-opportunities/using-syndemics-understand-hlbs-disease-emergence-and-progression-people-hiv <span class="field field--name-title field--type-string field--label-hidden">Using Syndemics to Understand HLBS Disease Emergence and Progression in People with HIV (PWH)(R01 Clinical Trial Not Allowed), expires 12/15/2021</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/vanselhj-0" typeof="schema:Person" property="schema:name" datatype="">vanselhj</span></span> <span class="field field--name-created field--type-created field--label-hidden">Fri, 10/09/2020 - 12:09</span> <a href="/tb-center/blog-post-rss/305" class="feed-icon" title="Subscribe to Using Syndemics to Understand HLBS Disease Emergence and Progression in People with HIV (PWH)(R01 Clinical Trial Not Allowed), expires 12/15/2021"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Application Due Date(s): January 11, 2021, and December 14, 2021</p> <p>This funding opportunity announcement is intended to support research project grant (R01) applications that propose to utilize a syndemics (synergistic epidemic) framework to elucidate the role of social, economic, environmental, behavioral, structural, psychological factors in promoting the synergistic interactions and clustering of heart, lung, blood, and sleep (HLBS) comorbidities among people with HIV at the population level. The ultimate goal is to identify strategies that foster holistic approaches in the clinical management of people living with HIV who have HLBS comorbidities, and to utilize existing data to assess the feasibility and cost-effectiveness of such approaches.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-018.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-018.html</a></p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=32" hreflang="und">NIH</a>, <a href="/tb-center/funding-opportunities?tag=41" hreflang="und">NHLBI</a>, <a href="/tb-center/funding-opportunities?tag=34" hreflang="und">HIV</a>, <a href="/tb-center/funding-opportunities?tag=58" hreflang="und">TB</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Fri, 09 Oct 2020 17:09:08 +0000 vanselhj 305 at https://www.vumc.org/tb-center Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed), expires 02/23/2021 https://www.vumc.org/tb-center/funding-opportunities/understanding-role-m-tuberculosis-granuloma-tuberculosis-tb-disease-and <span class="field field--name-title field--type-string field--label-hidden">Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed), expires 02/23/2021</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/vanselhj-0" typeof="schema:Person" property="schema:name" datatype="">vanselhj</span></span> <span class="field field--name-created field--type-created field--label-hidden">Thu, 10/01/2020 - 15:21</span> <a href="/tb-center/blog-post-rss/304" class="feed-icon" title="Subscribe to Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed), expires 02/23/2021"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>Application Due Date(s): February 22, 2021, All applications are due by 5:00 PM local time of applicant organization.</p> <p>To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for the development of improved therapeutic approaches.</p> <p><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-057.html">https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-057.html</a></p> </div> <div> <strong>Tags</strong> <div> <div><a href="/tb-center/funding-opportunities?tag=32" hreflang="und">NIH</a>, <a href="/tb-center/funding-opportunities?tag=46" hreflang="und">NIAID</a>, <a href="/tb-center/funding-opportunities?tag=58" hreflang="und">TB</a></div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Thu, 01 Oct 2020 20:21:55 +0000 vanselhj 304 at https://www.vumc.org/tb-center Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design https://www.vumc.org/tb-center/funding-opportunities/notice-special-interest-nosi-mechanisms-mycobacterial-induced-immunity-hiv <span class="field field--name-title field--type-string field--label-hidden">Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design</span> <span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="/tb-center/users/vanselhj-0" typeof="schema:Person" property="schema:name" datatype="">vanselhj</span></span> <span class="field field--name-created field--type-created field--label-hidden">Mon, 09/14/2020 - 12:44</span> <a href="/tb-center/blog-post-rss/303" class="feed-icon" title="Subscribe to Notice of Special Interest (NOSI): Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design"> RSS: <i class="fa fa-rss-square"></i> </a> <div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><div data-element-has-label="true" data-element-has-value="true" data-element-id="25861" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="OI">Notice Number:<span class="noticenum"> NOT-AI-20-071, expires: </span>January 08, 2023</div> <div data-element-has-label="true" data-element-has-value="true" data-element-id="25861" data-element-required="true" data-element-type="LINKED_ELEMENT" data-section-code="OI"> <div data-element-has-label="false" data-element-has-value="true" data-element-id="25871" data-element-required="true" data-element-type="TEXT" data-section-code="OI"> <p class="Normal">The purpose of this Notice of Special Interest (NOSI) is to stimulate innovative studies to identify and understand the immune responses that mediate protection fromMycobacterium tuberculosis(Mtb) infection or progression to active tuberculosis (TB) disease. Studies may focus on any stage of mycobacterial infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines and may include HIV-infected or uninfected individuals.</p> <p class="Normal">Research supported under this NOSI should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination are sought. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.</p> </div> </div> </div> <div class="field field--name-field-lockdown-auth field--type-string field--label-above"> <div class="field__label">Lockdown Auth</div> <div class="field__item">1</div> </div> Mon, 14 Sep 2020 17:44:34 +0000 vanselhj 303 at https://www.vumc.org/tb-center